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Abstract
Background: Visceral obesity is associated with the rising incidence of type 2 diabetes and metabolic syndrome. Low-grade
chronic inflammation and oxidative stress synergize in obesity and obesity-induced disorders.
Objective: We searched a cluster of molecules that support interactions between these stress conditions in monocytes.
Methods: RNA expressions in blood monocytes of two independent cohorts comprising 21 and 102 obese persons and 46
age-matched controls were determined by microarray and independently validated by quantitative RT-PCR analysis. The
effect of three-month weight loss after bariatric surgery was determined. The effect of RNA silencing on inflammation and
oxidative stress was studied in human monocytic THP-1 cells.
Results: Interleukin-1 receptor-associated kinase-3 (IRAK3), key inhibitor of IRAK/NFkB-mediated chronic inflammation, is
downregulated in monocytes of obese persons. Low IRAK3 was associated with high superoxide dismutase-2 (SOD2), a
marker of mitochondrial oxidative stress. A comparable expression profile was also detected in visceral adipose tissue of the
same obese subjects. Low IRAK3 and high SOD2 was associated with a high prevalence of metabolic syndrome (odds ratio:
9.3; sensitivity: 91%; specificity: 77%). By comparison, the odds ratio of high-sensitivity C-reactive protein, a widely used
marker of systemic inflammation, was 4.3 (sensitivity: 69%; specificity: 66%). Weight loss was associated with an increase in
IRAK3 and a decrease in SOD2, in association with a lowering of systemic inflammation and a decreasing number of
metabolic syndrome components. We identified the increase in reactive oxygen species in combination with obesity-
associated low adiponectin and high glucose and interleukin-6 as cause of the decrease in IRAK3 in THP-1 cells in vitro.
Conclusion: IRAK3 is a key inhibitor of inflammation in association with obesity and metabolic syndrome. Our data warrant
further evaluation of IRAK3 as a diagnostic and prognostic marker, and as a target for intervention.
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Introduction
Chronic low-grade inflammation is now considered to have a
pivotal role in the development of obesity and associated metabolic
diseases such as insulin resistance, type 2 diabetes (T2DM) and the
metabolic syndrome and cardiovascular disease [1,2]. It is
recognized that maladaptive production of various adipocytokines
(e.g. adiponectin, resistin, visfatin, and leptin) and pro-inflamma-
tory cytokines, such as tumor necrosis factor-a (TNFa) and
interleukin (IL)-6 and IL-1, are implicated in the development of
obesity-related systemic inflammation and insulin resistance. In
particular, the plasma levels of the adipocytokine adiponectin are
significant lower in obese individuals and have been associated
with inflammation, insulin resistance and the development of
cardiovascular disease. Adiponectin is present in the plasma in its
full length, forming homomultimers, and as globular adiponectin,
a shorter product formed by macrophage-dependent elastase
cleavage [3]. Globular adiponectin appears to be responsible for
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30414most biological effects of adiponectin [4,5]. The protective effect of
adiponectin has been attributed to its anti-inflammatory action
[6].
Consistent with their central role in coordinating innate
immunity and inflammation, the toll-like receptor family (TLRs)
and downstream transcription factor NFkB play critical roles in
obesity-associated inflammation. In particular, TLR2 and TLR4
are highly expressed in macrophages and adipose tissue and can
be activated by (saturated and oxidatively modified) fatty acids,
elevated during obesity, resulting in NFkB-dependent differenti-
ation with enhanced secretion of pro-inflammatory cytokines (e.g.
TNFa) [7,8]. Negative regulation of macrophage activation and
cytokine secretion primarily occurs at the signaling level.
Interleukin-1 receptor-associated kinase-3 (IRAK3; also referred
to as IRAKM) is a kinase-deficient member of the TLR/IRAK
family that has been shown to be an important negative regulator
of TLR-mediated cell signaling [9–11]. IRAK3 negatively
regulates signaling by preventing dissociation of IRAK1 and
IRAK4 from MyD88 and formation of IRAK – TNF receptor-
associated factor-6 (TRAF6) complexes. This protein has been
shown to regulate critical aspects of innate immunity [12,13].
IRAK3 expression is limited to cells of monocytic lineage [11] and
is a major mediator of globular adiponectin-induced endotoxin
tolerance in macrophages [14]. The role of this inhibitory protein
in regulating key aspects of macrophage polarization during
obesity-related inflammation and changes at its expression levels in
obesity has not yet been defined.
Obesity is also increasingly recognized as an oxidative stress
state, evidenced by the strong association between obesity and
circulating oxidized LDL (ox-LDL), which is a systemic marker of
oxidative stress [15–17]. In addition, reactive oxygen species
(ROS) play an important role in macrophage-mediated immunity
and the oxidation of specific epitopes, which at their turn are
important targets of innate immunity [18], emphasizing the
existence of a vicious circle between oxidative stress and
inflammation in obesity [19].
Considering the clear role of macrophages in the propagation of
inflammatory signals in adipose tissue, we wanted to identify
deregulated genes in circulating monocytes of obese individuals
and compare them with their expression pattern following weight
loss. Therefore, we collected monocytes of obese individuals and
performed microarray analysis followed by quantitative real-time
PCR (qRT-PCR) analysis on their extracts. We identified the
TLR2 signaling pathway as most deregulated canonical pathway
with IRAK3 as downregulated key inhibitor that is associated with
obesity-associated metabolic syndrome and loss of protective
action of adiponectin against cardiovascular disease.
Results
Study cohorts and metabolic parameters
The first cohort comprised 14 lean controls (29% male; age:
3363 years, mean 6 SEM) and 21 morbidly obese individuals
(33% male; age: 3963 years), without clinical symptoms of
cardiovascular disease. Obese subjects in the first cohort had
higher IL-6, high sensitivity C-reactive protein (hs-CRP), leptin
and glucose levels, and lower adiponectin levels, indicating the
presence of systemic inflammation. The higher levels of circulating
ox-LDL indicated systemic oxidative stress. Furthermore, insulin
and triglyceride concentrations were higher; HDL-cholesterol was
lower. Obese individuals had higher systolic and diastolic blood
pressure. Insulin resistance, calculated by a homeostasis model
assessment (HOMA-IR), was 86% higher in obese subjects
(Table 1A). A cluster of risk factors for cardiovascular disease
and T2DM including raised blood pressure, dyslipidemia (elevated
triglycerides and/or decreased HDL-cholesterol), raised fasting
glucose, and central obesity have become known as the metabolic
syndrome. A person qualifies for the metabolic syndrome with
three abnormal findings out of five [20]. Four controls used in this
study had 1 metabolic syndrome component; 1 had 2. Two obese
patients had 1, 7 had 2, 5 had 3, and 7 had 4 metabolic syndrome
components. Thus, 57% of the obese individuals had the
metabolic syndrome. Finally, we also collected blood of the obese
subjects three months after bariatric surgery. The blood
characteristics after short-term weight loss are depicted in
Table 1A. In aggregate, there was less systemic inflammation
but no reduction in circulating ox-LDL. Triglycerides, HOMA-IR
and adiponectin concentrations were restored to levels of lean
persons (Table 1A).
The second cohort consisted of 25 lean control and 102
successive obese women with (n=62) and without T2DM (n=40).
T2DM was defined according to the American Diabetes
Association. Obese women with T2DM were older (Table 2).
Compared to non-diabetics, diabetics had higher glucose and
insulin concentrations; their HDL-cholesterol was lower. Their
LDL-cholesterol was also lower due to more frequent use of statins
(78% vs. 30% of women without diabetes). This can also explain
lower ox-LDL concentrations in diabetics. IL-6 and hs-CRP levels
were not different between obese persons with and without
T2DM. Sixty percent of diabetics were treated with an ACE-
inhibitor, 51% with a beta-blocker, 15% with a calcium-
antagonist, and 44% with aspirin. Seven controls had 1, and 5
had 2 metabolic syndrome components. Three obese women
without T2DM had 1, 13 had 2, 14 had 3 and 10 had 4 metabolic
syndrome components. Thus 60% of them had the metabolic
syndrome. Four obese women with T2DM had 2, 12 had 3, 28
had 4, and 18 had all 5 metabolic syndrome components. Thus
94% of diabetics had the metabolic syndrome.
Identification and validation of IRAK3 as potential key
inhibitor of monocyte-related inflammation and
oxidative stress
Microarray analysis of RNA extracts from monocytes of a subset
of the first cohort (10 lean controls and 16 obese individuals)
identified 512 differentially expressed genes. Ingenuity metabolic
pathway analysis unveiled that the top five differentially regulated
molecular and cellular functions were cell signaling, cell death,
cellular growth and proliferation, cellular movement and cell-to-
cell signaling. Related to signaling, genes involved in the TLR
signaling, IL-6 and -10, circadian rhythm and PPAR signaling
were frequently deregulated with the TLR2-related signaling
pathway as most deregulated (11 out of 53 known key players were
deregulated, P=1.87610
25). Structural modeling by promoter
and gene annotation analysis of the deregulated genes in the TLR
signaling pathway revealed a theoretical model (Figure 1A)
containing TLR2 as cell surface marker, NFkB as transcription
factor, TNFa as inflammatory output, SOD2 as oxidative stress
marker, and IRAK3 and tumor necrosis factor alpha-induced
protein-3 (TNFAIP3) as putative inhibitors of the TLR2/NFkB
inflammatory pathway.
Figure 1B shows the expression of key molecules of the
theoretical model in human blood monocytes of the first cohort.
IRAK3, predominantly expressed in monocytes/macrophages, was
the only inhibitor of which the expression was decreased in obese
patients compared to lean controls and was associated with
increased inflammation, evidenced by increased expression of
TLR2 and TNFa. Increased oxidative stress was further evidenced
by decreased expression in genes involved in the oxidative defense
IRAK3 in Obesity and Metabolic Syndrome
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determined by qRT-PCR. However, these genes were not
differentially expressed at a P-value,0.01 after microarray
analysis.
To validate the observed expression profile, we determined the
gene expressions in blood monocytes of an independent second
cohort comprising 25 lean controls and 102 obese subjects
(Figure 1C). IRAK3 expression was decreased (-14%, P,0.001)
and associated with increased TNFa and SOD2 expressions. Gene
expressions of the IRAK3-related pathway, except TNFa, were not
different between obese patients with and without T2DM (Figure
S1).
Interestingly, a comparable expression profile was also detected
in visceral adipose tissue of obese subjects compared with adipose
tissue of lean controls (Figure 2A). Furthermore, markers of
adipocyte differentiation (PPARs, adiponectin (ADIPOQ)), insulin
signaling (insulin receptor (INSR)) and glucose uptake (glucose
transporter-4 (GLUT4)) were all decreased in adipose tissue of obese
patients (Figure 2B). IRAK3 correlated with PPARa, PPARc,
ADIPOQ, INSR and GLUT4 (rs=0.66, 0.43, 0.43, 0.52 and 0.47
respectively; all P,0.05).
Effect of short-term weight loss after bariatric surgery
Three-month weight loss after bariatric surgery was associated
with increased IRAK3 expression, and decreased inflammation and
oxidative stress (Table 1B). In addition, IRAK3 expression
correlated negatively with systemic IL-6 (rs=20.40, P,0.01),
ox-LDL (rs=20.32, P,0.05), and HOMA-IR (rs=20.42,
P,0.01). It correlated positively with blood adiponectin
(rs=0.28, P,0.05).
Association with metabolic syndrome
Receiver operating characteristic curve analysis revealed that
IRAK3 (mean AUC, 95%CI: 0.63, 0.54–0.72, P,0.05), TNFAIP3
(0.65, 0.56–0.73, P,0.01), SOD2 (0.69, 0.60–0.77, P,0.001), and
TNFa (0.71, 0.62–0.78, P,0.001) were associated with metabolic
syndrome. TLR2 was not.
Table 3 shows the odds ratios for metabolic syndrome in
relation to RNA expressions in monocytes determined by Chi-
square test with Yates’ correction. Odd ratios of high TNFAIP3,o r
high TNFa, or high SOD2, or low IRAK3 varied between 3 and 5.
These values were comparable to that of hs-CRP, using the
internationally accepted cut point of 3 mg/l. The value for the
Table 1. Characteristics and gene expressions before and after weight loss in obese patients (1
st cohort).
Lean controls (n=14) Obese patients (n=21)
Before weight loss After weight loss
A. Characteristics
Age (years) 33633 9 633 9 63
BMI (kg/m
2)2 1 614 4 61
*** 3661
***/$$$
Leptin (ng/ml) 8.761.4 65.668.0
*** 21.063.5
**/$$$
Adiponectin (mg/ml) 10.961.8 3.960.6
** 7.061.0
$$$
Glucose (mg/dl) 8362 11167
*** 8964
$$$
Insulin (mU/l) 10.361.8 16.562.1
** 6.360.8
$$$
HOMA-IR 2.160.4 3.960.5
** 1.860.2
$$$
Triglycerides (mg/dl) 8067 132611
*** 9968
$$
LDL-C (mg/dl) 110698 5 66
* 9263
HDL-C (mg/dl) 64644 9 63
** 4762
**
SBP (mmHg) 12063 13763
** 11861
$$$
DBP (mmHg) 75638 6 62
** 6261
***/$$$
IL-6 (pg/ml) 1.860.2 4.860.4
*** 3.460.4
***/$
Hs-CRP (mg/l) 0.4960.10 5.6561.13
*** 3.4560.82
**/$
Ox-LDL (IU/l) 50657 1 64
** 6964
**
B. Gene expressions
TLR2 0.9960.08 1.5460.06
*** 1.0260.09
$$$
IRAK3 0.9860.04 0.4960.03
*** 0.7960.05
**/$$$
TNFAIP3 1.0560.13 1.5460.11
*** 1.0360.11
$$
TNFa 1.0560.09 2.1860.31
*** 1.0660.12
$$
SOD2 1.0060.05 2.6560.28
*** 1.9160.19
***/$
Data shown are means 6 SEM.
*P,0.05,
**P,0.01 and
***P,0.001 obese compared with lean controls;
$P,0.05,
$$P,0.01 and
$$$P,0.001 compared with before weight loss;
Abbreviations: BMI, body mass index; C, cholesterol; DBP, diastolic blood pressure; HOMA-IR, homeostasis model assessment of insulin resistance; hs-CRP, high
sensitivity C-reactive protein; ox-LDL, oxidized LDL; SBP, systolic blood pressure.
doi:10.1371/journal.pone.0030414.t001
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increased to 9.3 when IRAK3 was low and SOD2 was high. Other
combinations did not yield higher odds ratios than that of separate
markers.
Regulation of IRAK3 expression in THP-1 monocytes
To identify the mechanistic link between obesity and IRAK3
depletion in circulating monocytes, we investigated the effect of
high (as in lean controls) and low (as in obese persons) levels of
adiponectin on IRAK3 expression. We determined the effect of
globular adiponectin because this domain of the adiponectin
protein appears to be responsible for most biological effects of
adiponectin [3,4]. Exposure of human monocytic THP-1 cells to
low levels of adiponectin resulted in a decreased expression of
IRAK3 (RNA and protein) compared to cells exposed to levels of
adiponectin present in lean controls and obese persons after weight
loss. This decrease was associated with more TNFa and
mitochondrial ROS (mROS) production. Interestingly, the anti-
inflammatory and anti-oxidative stress properties of high adipo-
nectin were nullified when IRAK3 was depleted by means of
siRNAs (Figure 3A).
As shown above, circulating ox-LDL levels, also associated with
metabolic disorders [17], were increased in obese patients,
remained high after weight loss (Table 1A) and correlated
negatively with IRAK3 expression in monocytes (rs=20.32,
P,0.05). The combined exposure of THP-1 cells to low
adiponectin and high ox-LDL, as in obese patients, resulted in
an additional decrease of IRAK3 (RNA and protein) compared to
cells exposed to low adiponectin alone (Figure 3A and 3B).
Interestingly, the IRAK3 expression in THP-1 cells exposed to
high adiponectin combined with high ox-LDL levels, characteristic
for obese patients after weight loss, resulted in an increased
expression of IRAK3, thus emphasizing that adiponectin is
essential to protect IRAK3 from inhibition by ox-LDL (Figure 3B).
Another blood component increased during obesity, decreased
after short-term weight loss and able to induce oxidative stress in
monocytes/macrophages, is glucose (Table 1A) [21]. Indeed,
short-term exposure of THP-1 cells to high glucose, comparable to
those in obese patients, resulted in increased mROS production
despite an increased expression of SOD2 (Figure 4A). Furthermore,
similar results were produced after exposure of THP-1 cells to the
cytokine IL-6, that is increased in obese subjects and decreased
after weight loss (Table 1A and Figure 4B). We thus hypothesized
that IRAK3-depletion together with an additional stress factor,
such as oxidative stress, triggers more inflammation and oxidative
stress in monocytes and adipose tissue macrophages. To test this
hypothesis, we exposed IRAK3-depleted THP-1 cells to an external
ROS source (glucose oxidase). Indeed, this resulted in more
inflammation and ROS production compared with non-exposed
IRAK3-depleted cells (Figure 4C).
Discussion
Although recent evidence shows that a vicious circle of chronic
inflammation and oxidative stress contribute to the development
of obesity and associated metabolic diseases, common inhibitors of
these processes have yet to be determined. Here, we identified
IRAK3 as a key inhibitor of TLR2/NFkB-mediated chronic
inflammation that is negatively associated with oxidative stress,
and obesity-related insulin resistance and metabolic syndrome. We
Table 2. Characteristics of obese women with and without T2DM for validation (2
nd cohort).
Lean controls (n=25) Obese women (n=102)
Without T2DM (n=40) With T2DM (n=62)
Age (years) 44624 8 62
* 5661
***/$$$
BMI (kg/m
2)2 2 60.3 3761
*** 3760.3
***
Leptin (ng/ml) 5.860.6 58.069.0
*** 4463.4
***
Adiponectin (mg/ml) 9.860.91 5.960.63
*** 5.260.61
***
Glucose (mg/dl) 87631 0 2 65
* 13566
***/$$
Insulin (mU/l) 7.961.0 17.163.5
*** 36.365.2
***/$$
HOMA-IR 1.760.2 4.661.0
** 1762.0
***/$$$
Triglycerides (mg/dl) 79661 2 6 611
*** 15368
***
LDL-C (mg/dl) 79651 0 2 66
* 7764
$$
HDL-C (mg/dl) 64635 3 62
** 4562
***/$$$
SBP (mmHg) 127631 3 4 63
** 13962
***
DBP (mmHg) 72628 2 68
** 8161
***
IL-6 (pg/ml) 2.660.1 4.660.5
*** 5.560.4
***
Hs-CRP (mg/l) 1.4260.44 6.6361.50
** 6.7960.98
***
Ox-LDL (IU/l) 36635 5 64
*** 4662
**/$
Data shown are means 6 SEM.
*P,0.05,
**P,0.01 and
***P,0.001 obese compared with lean controls;
$P,0.05,
$$P,0.01 and
$$$P,0.001 compared with obese women without T2DM;
Abbreviations: BMI, body mass index; C, cholesterol; DBP, diastolic blood pressure; HOMA-IR, homeostasis model assessment of insulin resistance; hs-CRP, high
sensitivity C-reactive protein; ox-LDL, oxidized LDL; SBP, systolic blood pressure; T2DM, type 2 diabetes.
doi:10.1371/journal.pone.0030414.t002
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before the development of T2DM and cardiovascular disease and
that its expression increased with weight loss. Interestingly, the
combination of low IRAK3 and high SOD2, a marker of
mitochondrial oxidative stress was the strongest predictor of
metabolic syndrome; it was even stronger than hs-CRP, the most
widely used marker of systemic inflammation that was shown to be
associated with metabolic syndrome [22,23]. We further identified
the mechanistic link between obesity and IRAK3 depletion in
circulating monocytes by exposing human monocytic culture cells
to variable concentrations of the obesity-associated hormone
adiponectin. We showed that low adiponectin levels are
responsible for the reduction in IRAK3 expression, which can
be further reduced by exposing monocytes to additional stress
factors such as ox-LDL. In addition, our results support a
bidirectional relation between adiponectin and IRAK3: high
adiponectin is required for upregulating IRAK3 in circulating
monocytes and IRAK3 is required for adiponectin to display anti-
oxidative and anti-inflammatory actions. The increased expression
of SOD2, observed in activated blood monocytes of obese subjects,
is possibly due to the increased systemic levels of IL-6 and glucose.
The exposure to IL-6 and glucose in THP-1 cells was
accompanied by increased mROS production despite the
increased expression of SOD2. Indeed, glucose is a known
substrate for ROS production in monocytes [21].
IRAK3 is an attractive candidate as inhibitor of monocyte-
related innate immune responses since it is exclusively expressed in
monocytes/macrophages and is a key inhibitor of TLR/NFkB
signaling [11]. Indeed, several recent studies have demonstrated
that IRAK3 regulates critical aspects of innate immunity,
including the development of endotoxin tolerance and sepsis-
induced alterations of antimicrobial responses [12,13]. Further-
more, IRAK3 is cleaved in alveolar macrophages during
pneumonia [24] and is an important regulator by which tumor-
associated macrophages mimic the phenotype of alternatively
activated (M2) macrophages [25]. However, the contribution of
this inhibitory protein to activating and tolerizing circulating
monocytes and macrophages during obesity-related inflammation
has not yet been defined. To address this, we used microarray
analysis to identify the most deregulated canonical pathway in
circulating monocytes of obese individuals. Indeed, the TLR2
signaling pathway with IRAK3 as key inhibitor was highly
deregulated in circulating monocytes and restored after short-term
weight loss associated with decreased systemic inflammation. In
addition, comparable changes in the IRAK3 expression profile
were detected in the visceral adipose tissue of obese subjects. This
is in agreement with the finding that obesity is associated with
enhanced activation of blood monocytes [26]. Thus, these results
indicate that IRAK3 is a potential key inhibitor of chronic
inflammation in blood monocytes and adipose tissue macrophages
associated with obesity, and related metabolic disorders such as
insulin resistance and metabolic syndrome.
Importantly, our in vitro data show that decreased systemic
adiponectin concentrations due to impaired adipogenesis can lead
Figure 1. IRAK3 is a key inhibitor in monocyte-related mechanisms underlying inflammation and oxidative stress during obesity.
(A) A structural model containing TLR2 as cell surface marker, NFkB as transcription factor, TNFa as inflammatory output, SOD2 as oxidative stress
marker, and IRAK3 and TNFAIP3 as putative inhibitors was determined by promoter and gene annotation analysis of deregulated genes. Flow of the
pathway at the protein interaction level is indicated by black arrows. Blunted arrows indicate inhibition. Phosphorylation is indicated by ???. Note that
NFkB is constitutively bound to IkB molecules, which confine its localization to the cytosol. IKK complex phosphorylation of IkB promotes its
degradation, thereby freeing NFkB to enter the nucleus and activate transcription of target genes. Gene expression of key molecules in the TLR2/
NFkB inflammatory pathway was measured by qRT-PCR in blood monocytes of (B) the first cohort comprising 14 lean controls and 21 obese patients,
and (C) the second cohort comprising 25 lean controls and 102 obese patients. Data are expressed as means.
**P,0.01 and
***P,0.001 obese persons
compared with lean controls.
doi:10.1371/journal.pone.0030414.g001
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of adiponectin are responsible for the decrease in IRAK3 and this
decrease can be amplified by additional exposure to systemic
stress factors such as ox-LDL. However, IRAK3 expression
depended on the adiponectin concentration rather than on the
ox-LDL concentration further emphasizing the causal role of
Figure 2. Gene expressions of the IRAK3-related pathway and adipocyte differentiation markers in visceral adipose tissue. (A) Gene
expression in visceral adipose tissue was analyzed by measuring relative RNA levels using qRT-PCR for key molecules in the TLR2/NFkB inflammatory
pathway. The adipose tissue specific antioxidant gene SOD3 instead of SOD2 was used as oxidative stress marker in visceral adipose tissue. (B)
Relative RNA levels of markers of adipocyte differentiation (PPARs and ADIPOQ), insulin signaling (INSR) and glucose uptake (GLUT4) in visceral adipose
tissue as determined by qRT-PCR. Data shown are means.
*P,0.05 and
**P,0.01 obese persons compared with lean controls; lean controls (n=7),
obese patients (n=21).
doi:10.1371/journal.pone.0030414.g002
Table 3. Association of RNA expressions in monocytes and blood levels with occurrence of metabolic syndrome.
Gene Cut point* OR Sensitivity (%) Specificity (%) PPV (%) NPV (%)
High TNFAIP3 $1.77 3.3 (1.5–7.2) 71 57 48 78
High TNFa $2.58 3.8 (1.8–8.2) 67 65 52 78
High SOD2 $1.67 4.5 (2.0–9.9) 71 65 52 80
Low IRAK3 #0.77 4.8 (1.5–14) 91 32 42 87
High CRP $3.0 4.3 (2.0–9.3) 69 66 53 79
Low IRAK3 or high TNFAIP3 As above 4.0 (1.8–8.6) 62 71 54 77
Low IRAK3 or high TNFa As above 4.6 (2.1–10) 64 72 56 79
Low IRAK3 or high SOD2 As above 6.9 (3.1–15) 69 76 61 82
High TNFa or high SOD2 As above 3.5 (1.7–7.6) 62 68 52 77
High TNFa or high TNFAIP3 As above 3.1 (1.5–6.7) 53 73 52 74
High TNFAIP3 or high SOD2 As above 4.0 (1.8–8.6) 62 71 54 77
Low IRAK3 and high SOD2 As above 9.3 (2.4–36) 91 77 61 85
*Cut points were determined by ROC curve analysis. Data are means (and 95% confidence intervals). Abbreviations: OR, odds ratio; NPV, negative predictive value; PPV,
positive predictive value.
doi:10.1371/journal.pone.0030414.t003
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monocytes. This is in agreement with the observations made
after short-term weight loss and between obese persons with and
without T2DM. Weight loss was associated with more systemic
adiponectin and IRAK3 expression despite the higher circulating
ox-LDL levels. Furthermore, obese patients with T2DM showed
lower levels of ox-LDL but no increase in IRAK3 expression.
However, it is possible that there is a relation between local
oxidative stress and IRAK3 expression. Indeed, we provided in
vitro evidence that exposure of IRAK3-depleted THP-1 cells to an
external ROS source, resulted in more inflammation and ROS
production supporting the in vivo observation that IRAK3-
depletion together with an additional stress factor enhances
inflammation and oxidative stress.
Overall, these data support the hypothesis that not the
reduction in adipose tissue per se, but the improved adipocyte
differentiation and resulting increase in adiponectin is the
mechanistic link with the changes in the expression of IRAK3
after weight loss. Interestingly, the anti-inflammatory and anti-
oxidative action of high adiponectin was nullified when IRAK3
expression was depleted by means of siRNA supporting the
recent finding that IRAK3 is a major mediator of the anti-
inflammatory properties of adiponectin [14]. This observation is
important in regard of adversative findings about the cardiopro-
tective effect of adiponectin. Indeed, in recent studies higher
adiponectin was associated with a significant increase in
cardiovascular disease mortality in patients with metabolic
diseases, and suggest that patients with low IRAK3 may not
benefit from treatment with adiponectin or adiponectin mimetics
[27,28].
Therefore, such RNA expression analysis can be used to develop
novel medical diagnostics for obesity-induced metabolic disorders
and more particular to identify patients that will not benefit
adiponectin treatment. Yet, the procedures for separating blood
cells and extracting RNA are technically complicated and time
consuming. However, these limitations may be overcome by using
recently microfluidic lab-on-a-chip technology. This, indeed,
represents a revolution in laboratory experimentation, bringing
Figure 3. Regulation of IRAK3 expression in THP-1 monocytes. (A) Gene expression was analyzed by measuring relative RNA levels using qRT-
PCR, protein expression and ROS production were determined by flow cytometry in THP-1 cells exposed to 1 or 10 mg/ml gADIPOQ (n=6) or in IRAK3-
depleted THP-1 cells exposed to 10 mg/ml gADIPOQ (n=4) for 6 h and 24 h. Data shown are means 6 SEM of 24 h exposed cells normalized to 6 h
exposed cells.
*P,0.05,
**P,0.01 and
***P,0.001 compared with THP-1 cells exposed to high gADIPOQ;
$$P,0.01 and
$$$P,0.001 compared with
THP-1 cells exposed to low gADIPOQ. (B) Gene/protein expression in THP-1 cells exposed to 10 mg/ml gADIPOQ and 10 mg/ml ox-LDL (n=6), 1 mg/ml
gADIPOQ and 25 mg/ml ox-LDL (n=6) or 10 mg/ml gADIPOQ and 25 mg/ml ox-LDL (n=6). Data are expressed as means 6 SEM.
**P,0.01 compared
with THP-1 cells exposed to 10 mg/ml gADIPOQ and 10 mg/ml ox-LDL;
$P,0.05 and
$$P,0.01 compared with THP-1 cells exposed to 1 mg/ml
gADIPOQ and 25 mg/ml ox-LDL. Abbreviations: gADIPOQ, globular adiponectin, iROS, intracellular ROS; mROS, mitochondrial ROS; ox-LDL, oxidized
LDL; ROS, reactive oxygen species.
doi:10.1371/journal.pone.0030414.g003
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together. Currently, lab-on-a-chips are already being used for
various applications in medicine and research, measuring specific
types of cells and molecules in a patient’s blood, and separating
biological molecules for laboratory analyses.
In summary, we have demonstrated a bidirectional relation
between adiponectin and IRAK3 in obesity. Low IRAK3 in
combination with high SOD2 expression is a marker of the
metabolic syndrome. In addition, the measurement of IRAK3 in
monocytes can be important for the identification of obese patients
that are more prone to adverse responses to adiponectin and
adiponectin mimetics.
Materials and Methods
Materials
All chemicals were obtained from Sigma-Aldrich, unless stated
otherwise. Polyclonal anti-IRAK3 antibody was purchased from
Rockland and Alexa647-conjugated goat anti-rabbit IgG from
Invitrogen. Human THP-1 monocytic cells (TIB-202) were
obtained from ATCC.
Patients and ethics statement
This study complies with the Declaration of Helsinki and the
Medical Ethics Committee of the Katholieke Universiteit Leuven
Figure 4. Exposure of IRAK3-depleted THP-1 cells to additional stress results in more inflammation and ROS. Gene expression was
analyzed using qRT-PCR and mROS production was determined by flow cytometry in THP-1 cells exposed to (A) 5.5 mM D-glucose and 9.5 mM D-
mannitol (osmotic control) or 15 mM D-glucose (n=6), and (B) 100 ng/ml IL-6 (n=6). Data shown are means 6 SEM.
*P,0.05,
**P,0.01 and
***P,0.001
compared with THP-1 cells exposed to 5.5 mM D-glucose or PBS vehicle. (C) Gene/protein expression and ROS production in THP-1 cells transiently
transfected with siRNA targeting IRAK3 (n=10) or in THP-1 cells exposed to 100 mU/ml glucose oxidase with (n=4) or without (n=5) silencing of IRAK3.
Data shown are means 6 SEM.
*P,0.05,
**P,0.01 and
***P,0.001 compared with THP-1 control cells or THP-1 cells transfected with negative control
siRNA;
$$P,0.01 and
$$$P,0.001 compared with THP-1 cells transfected with IRAK3 siRNA;
##P,0.01 and
###P,0.001 compared with THP-1 cells
exposed to glucose oxidase. Abbreviations: iROS, intracellular ROS; mROS, mitochondrial ROS; ROS, reactive oxygen species.
doi:10.1371/journal.pone.0030414.g004
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informed consent. The first cohort comprised 14 lean control
(27% male; WCF ,80 cm) and 21 obese individuals (33% male;
WCF: 128611 cm, mean 6 SEM). These 21 morbidly obese
subjects were referred to our hospital for bariatric surgery. Before
they were included, individuals were evaluated by an endocrinol-
ogist, an abdominal surgeon, a psychologist and a dietician. Only
after multidisciplinary deliberation, the selected patients received a
laparoscopic Roux-en-Y gastric bypass. A 30 ml fully divided
gastric pouch was created and the jejunum, 30 cm distal of the
ligament of Treitz, was anastomosed to it with a circular stapler of
25 mm. To restore intestinal transit, a fully stapled entero-entero
anastomose was constructed 120 cm distal on the alimentary limb.
In this way, the food passage was derived away from almost the
whole stomach, the duodenum and the proximal jejunum [29–31].
The metabolic syndrome was defined according to the joint
interim statement of 2009 [20]. The samples were collected
between March 29
th, 2005 and May 30
th, 2006. The second group
consisted of 25 lean control (WCF ,80 cm) and 102 successive
obese women with (n=62; WCF: 11562 cm) and without T2DM
(n=40; WCF: 12365 cm). T2DM was defined according to the
American Diabetes Association. The samples were collected at the
Division of Endocrinology between September 27
th and December
20
th, 2007. For analysis of the adipose tissue, we used the obese
patients of the first cohort and lean controls (n=7) that were
referred to the hospital for minor surgical interventions. All
participants were without symptoms of clinical atherosclerotic
cardiovascular disease.
Isolation of human monocytes
Blood samples were collected and after removal of the plasma
fraction, peripheral blood mononuclear cells (PBMCs) were
isolated using gradient separation on Histopaque-1077. Cells were
washed three times in Ca
2+- and Mg
2+-free Dulbecco’s (D)-PBS.
PBMCs were incubated with CD14 microbeads (20 ml/1610
7
cells) for 15 min at 4uC. Cells were washed once and re-suspended
in 500 mlC a
2+- and Mg
2+-free DPBS containing 0.5% BSA/1
610
8 cells. The suspension was then applied to an LS column in a
MidiMACS Separator (Miltenyi) [32,33]. We selected CD14
+
monocytes because CD14 intensity expression on circulating
monocytes was found to be associated with increased inflamma-
tion in patients with diabetes [34].
Blood analysis
Human blood samples were centrifuged to prepare plasma
samples for analysis. Total and HDL-cholesterol and triglyceride
levels were determined with enzymatic methods (Boehringer
Mannheim). LDL-cholesterol levels were calculated with the
Friedewald formula. Insulin resistance was calculated by a
homeostasis model assessment (HOMA)=fasting plasma insulin
(mU/L) x fasting blood glucose (mM)/22.5. Plasma glucose was
measured with the glucose oxidase method (on Vitros 750XRC,
Johnson & Johnson), and insulin with an immunoassay (Biosource
Technologies). Ox-LDL [35] (Mercodia), adiponectin, leptin and
IL-6 were measured with ELISA (R&D Systems). Hs-CRP was
measured on an Immage 800 Immunochemistry System (Beckman
Coulter). Blood pressure was taken three times with the participant
in a seated position after 5 minutes quiet rest. The average of the
last two measurements was used for systolic and diastolic blood
pressure. We tried to determine systemic TNFa levels in obese
individuals but the interwell variation within ELISA plates was
unacceptable. The coefficient of variance (%), defined as the
standard deviation divided by the overall mean, was 41%.
Cell culture
Human THP-1 monocytic cells were subcultured in RPMI
1640 (Gibco) as described previously in detail [36,37]. For globular
adiponectin incubation experiments, cells were cultured at a
density of 1610
6 cells/ml in RPMI 1640 supplemented with 10%
FBS and 5 mg/ml gentamicin. After 24 h, 1 or 10 mg/ml globular
adiponectin (PeproTech) was added and the cells were incubated
for 6 to 24 h. Globular adiponectin is a recombinant protein
derived from human globular domain adiponectin cDNA
expressed in Escherichia coli. This protein was endotoxin free (,2
EU/mg) according to the manufacturer. In addition, treatment of
cells with globular adiponectin (10 mg/ml) in the presence of
polymyxin B (50 mg/ml) did not affect globular adiponectin-
related TNFa expression (data not shown). The ox-LDL
incubation experiments were performed like previously described
[36]. To induce ROS formation in THP-1 cells, the cells were
incubated in RPMI 1640 containing 0.5% HSA in the absence or
presence of 100 mU/ml glucose oxidase. For glucose incubation
experiments, cells were cultured at a density of 1610
6 cells/ml in
glucose-free RPMI 1640 supplemented with 10% FBS, 5 mg/ml
gentamicin, and 5.5 mM D-glucose in a 5% CO2 incubator at
37uC. After 24 h, 9.5 mM D-glucose or 9.5 mM D-mannitol
(osmotic control) was added and incubated for 24 h under normal
growth conditions. For IL-6 experiments, THP-1 cells were
stimulated with 100 ng/ml recombinant IL-6 (PeproTech) for
24 h.
To deplete IRAK3 RNA, THP-1 cells were transiently transfect-
ed with chemical synthesized HP GenomeWide siRNAs (Qiagen;
human target sequence: 59-CACATTCGAATCGGTATATTA-
39 (Hs_IRAK3_5) and 59-CTGGATGTTCGTCATATTGAA-39
(Hs_IRAK3_6)). As a negative control, we used AllStars Negative
Control siRNA (Qiagen); as a positive control, we used Mm/
Hs_MAPK1 control siRNA (Qiagen; target sequence: 59-
AATGCTGACTCCAAAGCTCTG-39). Cells were transfected
with 50 nM of siRNA using HiPerfect reagent (Qiagen), according
to the manufacturer’s instructions with some modifications.
Briefly, THP-1 cells were seeded at a density of 1.5610
5/well
(24-well plate) in 100 ml of growth medium. Next, HiPerfect/
siRNA complexes (3 pmol of siRNA plus 6 ml of HiPerfect
reagent) were formed in 0.1 ml of serum-free RPMI-1640 for
10 min at room temperature and then added to each well. After
6 hours of incubation under normal growth conditions, 400 mlo f
growth medium was added to each well and the cells were
incubated for 42 hours. Gene silencing was monitored at the RNA
level by means of qRT-PCR and at the protein level using flow
cytometry. IRAK3-depleted THP-1 cells were exposed to globular
adiponectin or glucose oxidase as mentioned above.
Cell viability, as determined by trypan blue exclusion, was
.80%. mROS and iROS formation were measured with
MitoSOX and CM-H2DCFDA. Cells were incubated with PBS
containing 5 mM MitoSOX or 5 mM CM-H2DCFDA for 30 min-
utes at 37uC and5%CO2.Thelabeled cellswerewashed twicewith
PBS and then suspended in warm PBS for analysis by flow
cytometry (Becton, Dickinson and Company). For analysis of
IRAK3 protein expression, a total of 2610
5 treated THP-1 cells
were blocked with FcR blocking reagent (Miltenyi) for 10 min,
followed by fixation and permeabilization using a fixation/
permeabilization kit (Miltenyi), according to the manufacturer’s
instructions. Next, cells wereincubated with 2.5 mg/ml anti-IRAK3
antibody or isotype-matched control IgG at room temperature for
30 min. After washing, cells were incubated with 1 mg/ml
Alexa647-conjugated goat anti-rabbit IgG for another 30 min at
room temperature. Finally, the cells were washed twice, and
analyzed by flow cytometry (Becton, Dickinson and Company).
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analysis
Total RNA was extracted with TRIzol reagent (Invitrogen) and
purified on RNeasy Mini Kit columns (Qiagen). The RNA quality
was assessed with the RNA 6000 Nano assay kit using the Agilent
2100 Bioanalyzer.
Microarray analysis of RNA expression was performed with
Illumina’s Sentrix Human-6 v2 Expression BeadChip Kit
containing 46,713 probes/array targeting genes and known
alternative splice variants from the RefSeq database release 17
and UniGene build 188. RNA was labeled, hybridized and scanned
according to Illumina GLP standards by Aros AB laboratory. The
raw data were normalized with the rank-invariant method
(Illumina BeadStudio V2). This method uses a linear scaling of
the populations being compared. The scaling factor is determined
by rank-invariant genes. ‘‘Rank-invariant’’ genes are those genes
whose expression values show a consistent order relative to other
genes in the population. Of the 46,713 transcripts, 512 transcripts,
which were mapped in the Ingenuity Pathway Analysis (IPA)
program 5.5-802, were differentially expressed in monocytes of
obese patients compared to lean controls at a P-value,0.01.
Networks were built by means of the ‘‘Connect’’ and the ‘‘Path
explorer’’ tool in IPA. Canonical pathways were derived using the
‘‘Analysis’’ tool in IPA. In order to build the most representative
structural network starting from the deregulated genes in the TLR
signaling pathway, we used the GEMS MatInspector, Framewor-
ker, Gene2 promoter, and ElDorado software (Genomatix). The
significance of the association between the dataset and the
canonical pathway was measured in 2 ways. First, a ratio of the
number of genes that were differentially expressed in monocytes of
obese patients and were assigned to a particular signaling pathway
to the total number of genes that belong to this signaling canonical
pathway and were present on the microchip. Second, the Fischer’s
exact test was used to calculate a P-value determining the
probability that the association between the differentially
expressed genes in the dataset and the assigned genes in the
canonical pathway is not explained by chance alone. The
threshold was P=0.01. The data discussed in this publication
have been deposited in NCBI’s Gene Expression Omnibus [38]
and are accessible through GEO Series accession number
GSE32575 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE32575).
qRT-PCR is a commonly used validation tool for confirming
gene expression results obtained from microarray analysis. First-
strand cDNA was generated from total RNA with the SuperScript
VILO cDNA synthesis kit (Invitrogen). qRT-PCR was performed
on a 7500 Fast Real-Time PCR system using Fast SYBRGreen
master mix, according to the supplier protocols (Applied
Biosystems). Oligonucleotides (Invitrogen) used as forward and
reverse primers were designed using the ‘‘Primer Express’’
software (Applied Biosystems) and are summarized in Table S1.
RNA expression levels were expressed as the ratio compared to
controls as previously described [36,37].
Note that microarray and qRT-PCR data often result in
disagreement. It is well documented that both qRT-PCR and
microarray analysis have inherent pitfalls that may significantly
influence the data obtained from each method [39]. One of the
microarray-related pitfalls is the fact that some oligonucleotide
probes imprinted on the slide target the wrong gene [40]. One of
the important disagreements between microarray and qRT-PCR
analysis, was that the first identified IRAK3 as upregulated,
whereas the latter identified it as downregulated. To make sure
that primer sequences, used in qRT-PCR, target the right gene,
their specificity was validated by Basic Local Alignment Search
Tool (BLAST) [41]. Furthermore, cDNA clones (OriGene) for
IRAK3 (TNFAIP3 and SOD2) were used to double check the
primer specificity. In addition, PCR fragments were validated for
GC/AT ratio, length, and amplification specificity with dissoci-
ation curve analysis and agarose gel electrophoresis [42].
Statistical analysis
Lean and obese subjects were compared with an unpaired t-test
with Welch’s correction; obese subjects before and after weight loss
were compared with a paired t-test (two-tailed); in vitro data were
compared with the Mann–Whitney U test (GraphPad Prism 5).
Correlations were calculated using the nonparametric Spearman’s
correlation coefficient (rs). Receiver operating characteristic curve
(ROC) analysis was performed with MedCalc statistical software
for biomedical research. Odds ratios were determined by Chi-
square test with Yates’ correction (GraphPad Prism 5). A P-value
of less than 0.05 was considered statistically significant.
Supporting Information
Figure S1 Gene expression profile of obese women with
and without T2DM. Gene expression of key molecules in the
TLR2/NFkB inflammatory pathway in blood monocytes of 25
lean controls, 40 obese women without T2DM and 62 obese
women with T2DM. Data are expressed as means.
*P,0.05,
**P,0.01 and
***P,0.001 obese compared with lean controls;
$P,0.05 obese with T2DM compared with obese without T2DM;
Abbreviation: T2DM, type 2 diabetes.
(TIF)
Table S1 Primers used in qRT-PCR.
(DOC)
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